Opioid Maintenance: Terminable or Interminable; Implications for Theory, Treatment and Policy

Size: px
Start display at page:

Download "Opioid Maintenance: Terminable or Interminable; Implications for Theory, Treatment and Policy"

Transcription

1 Opioid Maintenance: Terminable or Interminable; Implications for Theory, Treatment and Policy Herbert D. Kleber, M.D. Professor of Psychiatry Director, Division on Substance Abuse Columbia University/NYSPI European and International Colloquium on Drug Addiction, Hepatitis and AIDS Biarritz, France 12 October, 2011

2 Whether individuals successfully maintained on Methadone can eventually be withdrawn and lead socially satisfactory and opiate free lives is a matter still not settled and open to vigorous debate. It is of course part of a larger issue, namely whether individuals dependent upon any opiate be it heroin or methadone can remain drug free and why or why not. Kleber HD, International J. Addiction, 1977

3 Early U.S. History (Con t) At beginning of 20 th Century, opiate withdrawal considered adequate for treatment of narcotic addiction Patients who relapsed did it from choice not necessitythus, moral degenerates Frequency of relapse led cities to set up narcotic clinics to legally provide heroin or morphine to addicts But short acting opiates required either multiple visits to clinic or take-home Deemed failures because did not lead to abstinence, & diversion occurred By 1923, all clinics were closed

4 Early History (Con t) 1914 Harrison Act interpreted as prohibiting maintenance of active addicts. Between , approximately 25,000 physicians indicted under the Harrison Act & 10% went to prison Physicians stop treating addicts for next 4 decades Treatment scarce, relapse common, prison frequent

5 Natural History 20 year follow-ups Vaillant 1973 Terms huezen 2005 Patients -100 NYC narcotics addicts 899 Amsterdam narcotics Admitted to Lexington 1962 addicts followed Followed For 20 yrs recruited from low threshold MM Deaths 23% - mostly of unnatural causes 27% died within 20 yrs after starting regular drug use, half from HIV related causes Abstinence % stable abstinence 27% abstinent from drugs + methadone Using 25% known to be using Unknown 10%

6 Methadone Maintenance Dole & Nyswander begin methadone maintenance,1964, at Rockefeller Institute; with assistance of Kreek Federal agencies look for excuses to shut it but Methadone Maintenance Treatment (MMT) expands 1968 Yale, Chicago and Phila. programs begin In Phila., district attorney threatened to arrest any doctor prescribing methadone to addicts Concerned about increased crime, Pres. Nixon announces War on Drugs, 6/17/71 Creates SAODAP - Dr. Jaffe becomes 1 st Drug Czar 2/3 s of $750 million 1974 drug budget for treatment etc. especially MMT; now 2/3 s supply

7 Opposition to Methadone Maintenance Reaction against MMT began quickly Substituting one addiction for another Psychosocial programs oppose it as likely to reduce concerns about poverty & social ills Some black leaders saw it as genocide, chilling out the ghetto without doing anything about racism, jobs, housing, & other ills Director of a therapeutic community, I think methadone is a great idea. We should give money to bank robbers, women to rapists, & methadone to addicts (1966) IOM report: current policy puts too much emphasis on protecting society from methadone & not enough on protecting society from the epidemic of addiction, violence, & infections methadone can help reduce. (1995)

8 Opposition to Methadone Maintenance (Cont) He (Bill W.) suggested that in my future research, I should look for a medication to relieve the alcoholic s sometimes irresistible craving and enable him to progress in AA toward social and emotional recovery (Dole, 1991) but many AA + NA groups oppose ONDCP states MMT both legitimate & important part of spectrum of drug abuse treatment Calls to dismantle or sharply curtail it continue from government officials

9 Methadone Maintenance (Con t) MMT s successes marked improvement in reducing illicit opioid use, morbidity & mortality, crime & risk of HIV infection, & in improving social & vocational functioning Approximate 260,000 in MMT in US & more than 1 million in world but some countries, e.g., Russia, forbid it Dose above 80mg usually better (e.g. Caplehorn, 1991; Ball 1988) Above 120mg better (e.g. Nosyk, 2009)

10 Effect of Methadone Maintenance on I.V. Use for 368 Male Methadone Patients in 6 programs At end of 1 st year, I.V. use down to 63.3% At end of 3 rd year I.V. Use down to 41.7% At end of 4 th year I.V. use down to 28.9% Crime also sharply dropped In 105 dropouts, 82% relapsed to I.V. use in 1 year Ball & Ross The Effectiveness of Methadone Maintenance Treatment, 1991

11 Methadone Effectiveness Methadone maintenance therapy versus no opioid replacement therapy (Review) 11 studies met the criteria for inclusion, all were randomized clinical trials Total of 1969 participants. Main results Methadone significantly more effective than nonpharmacological approaches in retaining patients suppression of heroin use as measured by self report and urine/hair analysis Difference not as great in criminal activity and mortality Mattick RP, Cochrane Database of Systematic Reviews 2009, Issue 3

12 Annual Rate Death Rates in Treated and Untreated Heroin Addicts Matched Cohort Methadone Voluntary Discharge Involuntary Discharge Untreated Gronbladh L, et al., Acta Psychiatr Scand, 1990

13 Methadone to Abstinence Tapering within a treatment environment supportive of both indefinite agonist treatment and medication tapering. records of (30) patients beginning a slow methadone taper were reviewed NONE successfully completed methadone tapering. 67% stopped taper 13% switched to bup 10% discharged, 10% continued taper Calsyn et al. 2006

14 Was difficulty to withdraw from MMT due to Detoxification Methods? 1980 s Clonidine (ROD) Rapid detoxification with clonidine and naltrexone 1990 s (UROD) ultra-rapid opiate detox under anesthesia; a number of deaths 2000 decade (BROD) Buprenorphine rapid detoxification Short Term Buprenorphine Taper No difference between 7 day and 28 day taper in those on Bup. only 1 month (Ling 2009) Adding Vivitrol post detoxification

15 Detoxification Although agonist maintenance therapies yield better outcomes most seek opioid withdrawal Primarily to lower cost of their habit or Pre-treatment before residential therapeutic community or opioid antagonist maintenance High relapse rates are probably less a function of withdrawal method & due more to reasons for seeking detoxification, post-withdrawal treatment, or brain changes developed during dependence Those who complete detoxification tend to have longer times to relapse than dropouts

16 Detoxification from heroin is good for many things but staying off heroin is not one of them Walter Ling

17 Reasons for Post-MMT Relapse Never achieved rehabilitated state - discharged Left program in good standing but Didn t feel ready to leave but under pressure from family or friends to do so Lack of employability skills and job Lack of non-using peer group While in treatment Comorbid psychiatric disorder not addressed Conditioned cues or coping with stress not addressed Dole Stupidity of thinking that just giving methadone will solve a complicated social problem seems to me beyond comprehension

18 Importance of Psychosocial Services in Methadone Maintenance Treatment 92 Male I.V. opiate users randomly assigned to one of 3 interventions when they entered the MMT 6 months Dose comparable in all groups at least 60 mg

19 Importance of Psychosocial Services in Methadone Maintenance Treatment (cont) Results MMS (methadone alone, no other services) had reduced opiate use but 69% had to be protectively transferred because of unremitting use of opiates or cocaine or medical / psychiatric emergencies SMS (Meth. + counseling) Treatment as usual 41% met criteria for transfer EMS (Enhanced services: Meth. + counseling and medical, psychiatric, employment and family therapy) 19% met criteria for transfer EMS>SMS>MMS in outcomes including employment, alcohol use, criminal activity and psychiatric status MMS patients transferred to SMS showed significant reductions in opiate and cocaine use in 4 weeks McLellan et al JAMA, 1993

20 Methadone Cash Cow CRC is Minting Money with Methadone CRC has become the country s largest dispenser of the drug by far, with 61 clinics scattered across many states. Jackson 2007 In 2008 half of M.M. pts. attended private for profit programs paying $13-$25/day Total spent for M.M.T.: $480 million year; $1 billion /yr (approx) Harwood, 2011

21 Decreased Psychosocial Services Services decreased in many programs because of switch to for-profit status Both quantity and quality of staff decreased Also because of cutbacks in state and federal funding

22 Harm Reduction Dilemma Should pts be discharged from MMT if, in spite of therapeutic intervention, behavior persists such as Continued high level of illicit opioids or cocaine Frequent missed meds or criminal behavior Violence towards staff or other pts OR kept on, risking contagion to other pts, negative community attitudes, forced closure of programs In short, increased stigma, decreased funding, increased group harm vs decreased individual harm Informal consensus: continued use of illicit opiates should not be reason for discharge but violence or other criminal behaviors should

23 Buprenorphine High affinity partial mũ agonist & kappa antagonist available as S.L. tablet and strip Reduced opioid agonist effects, with less respiratory depression (ceiling effect at mg) but need to be in withdrawal to begin. Users claim more clear-headed than methadone Possible relation to OPRL receptor 2 forms Mono (subutex) and Combo (suboxone) 4:1 ratio of bup/naloxone to reduce I.V. use Currently over 325K maintained, 40 K in detox, and 12 K prescribing Drs.

24 Buprenorphine Present Drs. required to have 8-hours of special training & X number Initially, Drs. restricted to 30 pts, led to long waiting lists & emphasis on detox Now permitted 100 patients after 1 year & ratio has switched to 75% maintenance But many Drs. neither refer nor give support

25 Opposition to Buprenorphine Backlash against buprenorphine For profit MMT programs fought against buprenorphine & filed petitions Diversion initially by street addicts to treat withdrawal but injection increasing DEA initially and currently concerned about bup. diversion as a schedule III. Has begun to inspect all Drs with X number Increased diversion in countries with only mono form

26 Number remaining in treatment Buprenorphine Maintenance vs Detox. RCT of cumulative retention in treatment deaths 10 5 Detox 1wk then Placebo 4 deaths Time from randomization (days) Number at risk Kakko, et al, Lancet, 2003

27 Addiction A chronic relapsing disease Genetic heritability, personal choice, and environmental factors involved in etiology and course as they are in type 2 diabetes and hypertension Addiction produces significant and lasting changes in brain chemistry and function but often treated as if it were an acute illness by Drs, family, insurers Relapse after detox. or other treatments is common There is no reliable cure for drug dependence Need to apply the strategies used in the treatment of other chronic illnesses to the treatment of drug dependence McLellan, et al JAMA, 2000 Could long term maintenance heal the brain? (Kreek)

28 Causes of Relapse Dole and Nyswander stress a metabolic deficiency either pre-existing or acquired Another major theory a conditioning model by Wikler (1971). O Brien, the heir to Wikler, showed in human lab studies that craving and withdrawal are conditioned responses with physiological concomitants (1977). Addiction is a learned response, a memory long after drugs were gone from the body Even slight W/D symptoms or anxiety can be relapse triggers. His group (1997) showed via brain imaging that drugrelated cues produce a conditioned limbic system activation and strong drug craving

29 Protracted Abstinence Syndrome (PAS) Chronic use of narcotic analgesics may induce physiological changes associated with an increased responsivity to stress responsible in part either directly or indirectly for relapse to narcotics use because of their capacity to diminish such responsivity 6-9 months are required before recovery from abstinence can be considered complete (May include dysphoria, fatigue, insomnia, irritability) William R. Martin Pathophysiology of Narcotic Addiction: Possible roles of Protracted Abstinence in Relapse -1972

30 The Reality of Terminable 50% of M.M. pts drop-out within 1 st year 1) Nearly 2/3 s of M.M. pts drop out within 1 st year 2) Those who drop out are likely to relapse quickly 3) 4) Most do so within 3 months after leaving 5) Reaching out to these pts after they leave led to many returning to treatment 6) 1) Simpson et al 1997, 2) Bell et al 2006, 3) Ball + Ross 1991, 4) Zanis et al 1996, 5) Hubbard and Marsden 1986, 6) Coviello et al 2011 About ½ of Bup. pts drop out by 6 months Withdrawal from last 2mg of bup. may be especially difficult

31 Terminable or Interminable Options Terminable Maintenance till socially rehabilitated (at least 1-3 years) followed by: Short term tapering or 6 month taper Either followed by long acting narcotic antagonist Indefinite Maintenance The optimal duration of M.M. or Bup.is not yet known and varies by individual For most patients, longer duration appears associated with better outcomes Alternatives: antagonist maintenance; T.C; AA.

32 Unresolved Questions Role of age of onset and duration of addiction Street heroin users vs prescription opioid abusers Role of comorbid and genetic factors Role of length of time on maintenance opioid

33 Recovery A voluntarily maintained lifestyle characterized by sobriety, personal health, and citizenship JSAT 2008 Recovery can be achieved without medication - and it can also be achieved with it. McLellan, 2010

34 The descent to Hell is easy; the gates stand open day and night; but to reclimb the slope, and escape to the upper air, this is labor. Virgil, The Aeneid Book VI, Line 126

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011 Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids

More information

Medication-Assisted Addiction Treatment

Medication-Assisted Addiction Treatment Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

Treatment of opioid use disorders

Treatment of opioid use disorders Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence

More information

Using Drugs to Treat Drug Addiction How it works and why it makes sense

Using Drugs to Treat Drug Addiction How it works and why it makes sense Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic

More information

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate

More information

How To Treat Anorexic Addiction With Medication Assisted Treatment

How To Treat Anorexic Addiction With Medication Assisted Treatment Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious

More information

DrugFacts: Treatment Approaches for Drug Addiction

DrugFacts: Treatment Approaches for Drug Addiction DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please

More information

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry

More information

Buprenorphine Therapy in Addiction Treatment

Buprenorphine Therapy in Addiction Treatment Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

Update on Buprenorphine: Induction and Ongoing Care

Update on Buprenorphine: Induction and Ongoing Care Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference

More information

OVERVIEW OF MEDICATION ASSISTED TREATMENT

OVERVIEW OF MEDICATION ASSISTED TREATMENT Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the

More information

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by

More information

Buprenorphine: what is it & why use it?

Buprenorphine: what is it & why use it? Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation

More information

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2011 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2015 May 2015 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research

More information

EPIDEMIOLOGY OF OPIATE USE

EPIDEMIOLOGY OF OPIATE USE Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months

More information

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Dependence and Addiction Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Overview Heroin and other opiates The disease of heroin addiction or dependence Effective

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and

More information

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,

More information

Frequently asked questions

Frequently asked questions Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs

More information

Putting Addiction Treatment Medications to Use: Lessons Learned

Putting Addiction Treatment Medications to Use: Lessons Learned Putting Addiction Treatment Medications to Use: Lessons Learned George E. Woody, M.D. Laura McNicholas, M.D., Ph.D. Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia

More information

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid

More information

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines

More information

MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT. An Outpatient Model

MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT. An Outpatient Model MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT An Outpatient Model OBJECTIVE TO PRESENT A PROTOCOL FOR THE EVALUATION AND TREATMENT OF PATIENTS WHO ARE CHEMICALLY DEPENDENT ON OR SEVERLY

More information

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015 Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid

More information

Joel Millard, DSW, LCSW Dave Felt, LCSW

Joel Millard, DSW, LCSW Dave Felt, LCSW Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used

More information

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents

More information

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for

More information

Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services. Lea Goldstein, Ph.D. Brian Greenberg, Ph.D.

Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services. Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. The Narcotic Replacement Therapy (NRT) Policy Narcotic replacement programs

More information

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,

More information

CLINICAL POLICY Department: Medical Management Document Name: Vivitrol Reference Number: NH.PHAR.96 Effective Date: 03/12

CLINICAL POLICY Department: Medical Management Document Name: Vivitrol Reference Number: NH.PHAR.96 Effective Date: 03/12 Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

One example: Chapman and Huygens, 1988, British Journal of Addiction

One example: Chapman and Huygens, 1988, British Journal of Addiction This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman

More information

Using Buprenorphine in an Opioid Treatment Program

Using Buprenorphine in an Opioid Treatment Program Using Buprenorphine in an Opioid Treatment Program Thomas E. Freese, PhD Director of Training, UCLA Integrated Substance Abuse Programs Director, Pacific Southwest Addiction Technology Transfer Center

More information

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently

More information

Understanding Addiction: The Intersection of Biology and Psychology

Understanding Addiction: The Intersection of Biology and Psychology Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November

More information

John R. Kasich, Governor Orman Hall, Director

John R. Kasich, Governor Orman Hall, Director John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic

More information

Patients are still addicted Buprenorphine is simply a substitute for heroin or

Patients are still addicted Buprenorphine is simply a substitute for heroin or BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute

More information

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,

More information

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment

More information

Opioid Addiction & Corrections

Opioid Addiction & Corrections Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and

More information

TREATMENT MODALITIES. May, 2013

TREATMENT MODALITIES. May, 2013 TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.

More information

Opioid Treatment Services, Office-Based Opioid Treatment

Opioid Treatment Services, Office-Based Opioid Treatment Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,

More information

Medication-Assisted Treatment for Opioid Addiction

Medication-Assisted Treatment for Opioid Addiction Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid

More information

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics

More information

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine

More information

Update and Review of Medication Assisted Treatments

Update and Review of Medication Assisted Treatments Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment

More information

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of

More information

Beyond SBIRT: Integrating Addiction Medicine into Primary Care

Beyond SBIRT: Integrating Addiction Medicine into Primary Care Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison

More information

Prescriber Behavior, Pain Treatment and Addiction Treatment

Prescriber Behavior, Pain Treatment and Addiction Treatment Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy

More information

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction

More information

Heroin Overdose Trends and Treatment Options. Neil A. Capretto, D.O., F.A.S.A.M. Medical Director

Heroin Overdose Trends and Treatment Options. Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds

More information

Opioid/Opiate Dependent Pregnant Women

Opioid/Opiate Dependent Pregnant Women Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than

More information

EPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.

EPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH. Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF

More information

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical

More information

5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome

5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome 5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is

More information

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol. Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.

More information

Addiction Pharmacotherapies in Integrated Systems OPIOIDS

Addiction Pharmacotherapies in Integrated Systems OPIOIDS Addiction Pharmacotherapies in Integrated Systems OPIOIDS Univ. Prof. Dr.. Gabriele Fischer Department of Psychiatry Addiction clinic Medical University Vienna DELIVERY SYSTEMS FOR SUBSTANCE ABUSE TREATMENT

More information

Use of Buprenorphine in the Treatment of Opioid Addiction

Use of Buprenorphine in the Treatment of Opioid Addiction Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an

More information

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D.

More information

Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1

Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1 Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1 Disclosure Statement Prevalence of Opioid Addiction 100 Individuals Die Every

More information

Information for Pharmacists

Information for Pharmacists Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl

More information

The Science of Addiction and Its Effective Treatment

The Science of Addiction and Its Effective Treatment The Science of Addiction and Its Effective Treatment Anne Arundel County Opioid Misuse and Overdose Symposium April 15, 2015 D. Andrew Tompkins, M.D. M.H.S. Agenda 1. Terminology a. Addiction versus Substance

More information

Medication Assisted Treatment

Medication Assisted Treatment Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice

More information

Opiate Abuse and Mental Illness

Opiate Abuse and Mental Illness visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program [email protected]. The West Virginia Model

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model West Virginia University School of Medicine BEHAVIORAL MEDICINE & PSYCHIATRY Morgantown, WV Carl R. Sullivan, M.D. Professor and Director Addictions Program [email protected] Disclosure Reckitt Benckiser

More information

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification

More information

From the street to the NICU. Richard Christensen, PA, CAS

From the street to the NICU. Richard Christensen, PA, CAS From the street to the NICU Richard Christensen, PA, CAS Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a stand-alone

More information

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids

More information

The ABCs of Medication Assisted Treatment

The ABCs of Medication Assisted Treatment The ABCs of Medication Assisted Treatment J E F F R E Y Q U A M M E, E X E C U T I V E D I R E C T O R C O N N E C T I C U T C E R T I F I C A T I O N B O A R D The ABCs of Medication Assisted Treatment

More information

drug treatment in england: the road to recovery

drug treatment in england: the road to recovery The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:

More information

Medication is not a part of treatment.

Medication is not a part of treatment. Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained

More information

Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling

Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate

More information

Treatment of Prescription Opioid Dependence

Treatment of Prescription Opioid Dependence Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription

More information

Treatment of Opioid Addiction. Miriam Komaromy, MD Associate Director, Project ECHO University of New Mexico Health Sciences Center

Treatment of Opioid Addiction. Miriam Komaromy, MD Associate Director, Project ECHO University of New Mexico Health Sciences Center Treatment of Opioid Addiction Miriam Komaromy, MD Associate Director, Project ECHO University of New Mexico Health Sciences Center Why does the human brain become addicted? Why can we only become addicted

More information

Alcohol intervention programs in other countries

Alcohol intervention programs in other countries Alcohol intervention programs in other countries Assist. Prof. Dr. Suttiporn Janenawasin Siriraj Hosp. Mahidol Univ. A Major Task for Drug Treatment is Changing Brains Back! The Most Effective Treatment

More information

The story of drug treatment

The story of drug treatment EFFECTIVE TREATMENT CHANGING LIVES www.nta.nhs.uk www.nta.nhs.uk 1 The story of drug treatment The use of illicit drugs is declining in England; more and more people who need help with drug dependency

More information

ANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting

ANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting ANCILLARY STABILIZATION AND WITHDRAWAL The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting About CASAColumbia A science-based, multidisciplinary organization Focused on transforming

More information

Expanding access to treatment for opiate addiction: Successes and Barriers

Expanding access to treatment for opiate addiction: Successes and Barriers Expanding access to treatment for opiate addiction: Successes and Barriers Miriam Komaromy, MD Medical Director, Turquoise Lodge Addiction Treatment Hospital, NM Department of Health; and UNM Project ECHO

More information

Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.

Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive. Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.

More information

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This

More information

MAT Counselor Education Course Exam Questions Packet Part 1

MAT Counselor Education Course Exam Questions Packet Part 1 MAT Counselor Education Course Exam Questions Packet Part 1 Course No: Course Title: Course Objective: MA-1901P1 Medication-Assisted Treatment (MAT) Counselor Education Course Part 1 Includes primer on

More information